STOK
Stoke TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-22
+
Peers tracked
11
U.S. public peers
Grade Position
Below peers
vs peer average
STOK vs peer average
44/100
STOK vs. peer average (D vs. D)
Grade spread
A 1 · C 3 · D 5 · F 2
Graded peers loaded
Coverage
11 graded
100% of tracked
Peer overview
INBX is the first available peer comparator.
Inhibrx Biosciences is a closer-size clinical biotech comp where valuation is also milestone-driven and commercial revenue is not the support; it is useful for binary-development and funding-risk framing, though the indication set is different.
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
STOK
Stoke Therapeutics
INBX
Inhibrx Biosciences
Grade
D
F
Momentum
16
26
Value
49
41
Sentiment
66
0
Setup Bias
Net —
-
Market Cap
-
-
Posture
Defensive
Defensive
Grade position vs INBX
STOK / INBX
Grade Position
Below peers
STOK vs. peer average (D vs. D)
44/100
Momentum
16
INBXValue
49
STOKSentiment
66
STOKRotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs STOK
INBX is the first peer returned for this comparison set.